{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:04:47Z","timestamp":1648699487430},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.leukres.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,4,28]],"date-time":"2013-04-28T14:15:27Z","timestamp":1367158527000},"page":"729-730","source":"Crossref","is-referenced-by-count":5,"title":["The role of comorbidities in chronic myeloid leukemia"],"prefix":"10.1016","volume":"37","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.04.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2012.01.001","article-title":"Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data","author":"Breccia","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2013.04.001_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10428194.2010.546920","article-title":"Mechanisms of resistance to BCR-ABL kinase inhibitors","volume":"52","author":"Diamond","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2013.04.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.04.001_bib0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/11591840-000000000-00000","article-title":"Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients","volume":"25","author":"Breccia","year":"2011","journal-title":"BioDrugs"},{"key":"10.1016\/j.leukres.2013.04.001_bib0025","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood.V120.21.1676.1676","article-title":"ENESTnd 4-year update: continued superiority of nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosomepositive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.04.001_bib0030","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.04.001_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0021-9681(70)90054-8","article-title":"The pre-therapeutic classification of comorbidity in chronic disease","volume":"23","author":"Feinstein","year":"1970","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.leukres.2013.04.001_bib0040","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.leukres.2013.04.001_bib0045","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.04.001_bib0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14740331003742935","article-title":"Pleural\/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to theur development","volume":"9","author":"Breccia","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.leukres.2013.04.001_bib0055","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.leukres.2013.04.001_bib0060","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.leukres.2012.03.010","article-title":"Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.04.001_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.04.001_bib0070","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.04.001_bib0075","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood.V120.21.3756.3756","article-title":"Analysis of clinical arterial and metabolic parameters in chronic phase CML patients on nilotinib in a single center cohort","volume":"120","author":"Labussiere-Wallet","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.04.001_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2012.12.018","article-title":"Delayed cytogenetic and major molecular responses associated to increate BMI at baseline in chronic myeloid leukemia patients treated with imatinib","author":"Breccia","year":"2013","journal-title":"Cancer Lett"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T22:39:25Z","timestamp":1595716765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0145212613001094"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.04.001","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}